Uracil derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and matrix
metalloproteinases
申请人:——
公开号:US20030229081A1
公开(公告)日:2003-12-11
The present application describes novel uracil derivatives of formula I:
A-W-U-X-Y-Z-U
a
-X
a
-Y
a
-Z
a
I
or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, U
a
, X
a
, Y
a
, and Z
a
are defined in the present specification, which are useful as inhibitors of TNF-&agr; converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof.
本申请描述了式I的新颖尿嘧啶衍生物:A-W-U-X-Y-Z-Ua-Xa-Ya-Za或其药用可接受的盐或前药形式,其中A、W、U、X、Y、Z、Ua、Xa、Ya和Za在本规范中有定义,这些衍生物可用作肿瘤坏死因子α转化酶(TACE)、基质金属蛋白酶(MMP)、聚集素酶的抑制剂或其组合。